Effect of Platelet Count on Prognostic Value in Patients with Chronic Heart Failure

Zhi Li (lizhi519@126.com)
Shantou University
https://orcid.org/0000-0002-9200-5612

Zhenyu Jiao
Beijing Chao-Yang Hospital: Beijing Chaoyang Hospital

Yang Xie
Second Affiliated Hospital of Shantou University Medical College

Yanbing Li
Beijing Chao-Yang Hospital: Beijing Chaoyang Hospital

Research article

Keywords: Platelet count, Prognostic value, Chronic heart failure

DOI: https://doi.org/10.21203/rs.3.rs-115907/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: The prognostic value of platelet count in chronic heart failure (CHF) is not clearly established. The present study aimed to assess the independent prognostic value of platelet count in patients with CHF.

Methods: From January 2016 to December 2019, 1162 patients with a discharge diagnosis of CHF were recorded in the present study. The patients were divided into two groups according to the platelet count: low platelet count (LP, ≤140,000/μl) and high plate count (HP, >140,000/μl). The main outcomes were defined as all-cause death or cardiogenic rehospitalization within 3 years. Survival analysis and Cox proportional hazard models adjusted by an established risk score were performed.

Results: During 3 years follow-up, the overall main outcomes including all-cause death (P=0.0475) and composite endpoint events of all-cause death or cardiogenic rehospitalization (P=0.0053) were higher in LP group than in those with HP group. After adjusting for other covariables, including gender, age, et al., low platelet count was related to increased the risk of main outcomes during 3 years follow-up (all-cause death, HR: 1.151, 95%CI: 1.082-1.670, P=0.040; composite endpoint events, HR: 1.313, 95%CI: 1.152-1.964, P=0.016).

Conclusions: Low platelet count was associated with risk for higher adverse outcome in patients with CHF.

Background

In recent years, although there have been progress in the treatment of chronic heart failure (CHF), it remains a major public-health issue with high associated risks of morbidity and mortality and substantial associated economic costs. CHF patients are often admitted to the hospital with acute onset of symptoms. Although various mechanisms have been commented, the causes of the development of acute decompensation in patients with stable CHF are still illegible. As well as, a reliable, simple, inexpensive and rapid prognostic marker for CHF patients is obviously needed.

Although CHF is well known to be associated with a prothrombotic or hypercoagulable state, the pathophysiology of thromboembolism in CHF is multifactorial and complex. Indeed, abnormalities in hemorheological function has been confirmed in CHF, while elevated markers of platelet activity. Platelets are essential for maintaining the integrity of the vascular system and are the first line of defense against bleeding. Chronic platelet activation is associated with an increased risk of capillary thrombosis [1]. A recent study carried out by Satoshi et al. [2] showed that low blood platelet count was a risk factor of all-cause death and the composite endpoint events in patients with CHF. The mean platelet volume, which represents platelet activation, was associated with the risk of heart failure hospitalization in patients with CHF [3]. Recent study reported that prognostic value of mean platelet volume in cardiovascular pathology [4–7], including correlation between mean platelet volume and exacerbated heart failure [8]. Several previous researches have illustrated that pro-thrombotic state and blood platelet activation are related to...
the severity of acute heart failure and the underlying risk of heart failure worsening in patients with CHF. At the same time, age-related decrease in blood platelet count has been reported among healthy people [9]. However, it is reported that patients with symptomatic CHF have bone marrow dysfunction regardless of age [10]. In addition, in patients diagnosed with heart failure with reduced left ventricular ejection fraction for the first time, lower blood platelet count was a risk factor for 1-year mortality [11]. However, the prognostic value of platelet count in CHF remains illegible.

We have therefore undertaken a study to evaluate the effect of platelet count on prognostic value in patients with CHF. We sought to define the relationship of blood platelet count and CHF-related adverse outcomes of all-cause death and cardiogenic rehospitalization in patients with CHF.

**Methods**

**Patients**

The study population consisted of 1162 consecutive patients with exacerbated heart failure diagnosed with CHF, admitted to the Beijing Chaoyang Hospital and Second Affiliated Hospital of Shantou University Medical College from January 2016 to December 2019. The diagnosis of CHF was adjudicated by 2 independent cardiologists according to the American College of Cardiology/American Heart Association guidelines [12] for CHF. In the case of patients admitted on more than once during the study period, the only data included in the analysis were those corresponding to the first admission. Patients with acute coronary syndromes, severe infection, cancer, liver and renal dysfunction (eGFR < 60 ml/min/1.73 m²) were excluded (Fig. 1). The whole group was divided into 2 subgroups according to the basic platelet count: low platelet count group (LP, platelet count ≤ 140,000/µl) and high platelet count group (HP, platelet count > 140,000/µl).

The protocol was approved by the Institutional Ethics Committee at the Beijing Chaoyang Hospital and Second Affiliated Hospital of Shantou University Medical College (No. SUMC2020-009). Patients were not required to provide written consent to enter the clinical database, since this was part of the routine clinical operations in the CHF clinic.

**Data collection**

Hematological and biochemical measurements made at the time of admission were analyzed. Baseline information was obtained on demographic variables, medical history, medication use (medication on discharge), the main clinical findings upon admission, risk factors and supplementary examinations (echocardiography, electrocardiography). The results were obtained from the patients’ medical histories.

**Study endpoints**

Data for each patient were censored 3 years after admission, so that there was 3 years follow-up for each patient. The primary end point of the study is defined as time from the first occurrence of death from any cause. Second outcomes included rates of composite endpoint events of all-cause death, 3-year
cardiogenic readmission to the hospital for unstable angina, worsening heart failure, stroke or myocardial infarction occurring during any rehospitalization.

**Statistical analysis**

Continuous data are expressed as mean ± SD. Comparison of Continuous variables between LP and HP group was performed using Student's t-tests and chi-squared test or Fisher exact test, as appropriate for qualitative variables, either categorical or ordered. The unadjusted cumulative survival and incidence of the endpoint events (all-cause death and combined endpoint events of all-cause death or cardiogenic rehospitalization) for patients with low and high blood platelet count were compared using Kaplan-Meier survival analyses and statistical significance was tested using a log rank test. Hazard ratios were generated by a Cox regression analysis. We used a Cox proportional hazard model with backward elimination to estimate adjusted hazard ratios. The resulting regression coefficients were used to estimate relative risks (RR) and the corresponding 95% confidence intervals (CI). A P value of < 0.05 was considered statistically significant. Statistical analysis was performed with GraphPad Prism 7.0 and SPSS for Windows Version 17.0 (SPSS, Chicago, IL).

**Results**

**Baseline characteristics**

Of the 1162 patients, 566 (48.7%) patients with low platelet count and 596 (51.3%) patients with high platelet count and baseline characteristics are summarized in table 1.

In general (table 1), patients with low platelet count mostly were old (years, 78.69 ± 15.38 vs. 74.07 ± 10.89, P<0.01) and female subjects (44.2% vs. 36.5%, P<0.01) with a history of valvular disease (27.4% vs. 11.1%, P<0.01) and diabetes mellitus (26.9% vs. 16.6%, P<0.01). Ischemic heart disease was the slightly more common etiology of CHF with low platelet count (64.0% vs. 58.9%, P=0.072), and more common combine with atrial fibrillation (38.9% vs. 33.3%, P=0.047). Patients with low platelet count were also more likely to have a longer history of heart failure.

Patients with low platelet count had a slightly but significantly lower mean LVEF compared with patients with high platelet count (47.11 ± 15.47% vs. 49.41 ± 14.56%, P<0.009). NT-pro-BNP, hs-TnT, left atrial and left ventricular dimension were generally higher in patients with low platelet count. There was no difference in essential hypertension and medication use.

**Survival Analysis**

During the 3-year follow-up, a total of 199 (17.1%) deaths occurred, and 590 (50.8%) patients died or readmitted to hospital because of worsening heart failure, unstable angina, myocardial infarction or stroke occurring during any hospitalization. The unadjusted 3-year end point of all-cause death was 107 (18.9%) for patients with low platelet count and 92 (15.4%) for those with high platelet count (figure 2A,
Log rank P=0.0475), and unadjusted combined 3-year end point of death and readmission was 309 (54.6 \%) for patients with low platelet count and 281 (47.1\%) for those with high platelet count (figure 2B, Log rank P=0.0053), respectively.

**Predictors of end point events of all-Cause Death**

On Cox Proportional hazard model for adverse outcomes of all-cause death univariate and multivariable analysis (table 2), after adjustment for demographic and clinical covariates of underlying prognostic impact, low platelet count of blood was associated with increase the relative risk of 3-year overall mortality (HR=1.151, 95%CI: 1.082-1.670, \(P=0.040\)). Furthermore, a similar result was obtained on high sensitive troponin T (hs-TnT) in Cox multivariable analysis for all-Cause Death (table 2), elevated serum hs-TnT was a dependent risk factor for 3-year all-cause death in CHF (HR=1.680, 95%CI: 1.485-1.953, \(P=0.029\)).

**Predictors of end point events of all-cause death and cardiogenic readmission**

In all-cause death and cardiogenic readmission univariate Cox analysis demonstrated that heart rate, age, systolic/diastolic blood pressure, history of CHF, LAD, platelet count of blood and hs-TnT were significant risk factors for the combined endpoint of all-cause death and cardiogenic readmission in CHF (Table 3). Nevertheless, after adjustment for other covariates of lurking prognostic impact, heart rate, systolic/diastolic blood pressure and LAD were not associated with significant higher risk of 3-year composite endpoint of all-cause death and cardiogenic readmission (table 3).

In the Cox proportional hazards model (table 3), variables associated with an increased risk of 3-year composite endpoint of all-cause death and cardiogenic readmission included low platelet count of blood (HR: 1.313, 95%CI: 1.152-1.964, \(P=0.016\)), hs-TnT (HR: 2.411, 95%CI: 1.433-4.056, \(P=0.003\)) and age (HR: 1.009, 95%CI: 1.001-1.016, \(P=0.021\)) (table 3).

**Discussion**

As far as we know, the present study demonstrated that the progressive prognostic value of blood platelet count in CHF for the first time. Our results showed low blood platelet count was a dependent risk factor for adverse outcomes of all-cause death and the combined endpoint events of all-cause death and cardiogenic rehospitalization in patients with CHF. These findings are consistent with data reported in patients with acute heart failure in other studies \[2\]. Moreover, we also present the first-ever analysis of advered outcomes risk markers in patients with CHF and show that hs-TnT, age and history of CHF as independent predictors of all-cause death and cardiogenic rehospitalization in patients with CHF.

**CHF and blood platelet count**
Platelets are crucial for maintaining the integrity of the vascular system and are the first line of defense against bleeding. Blood platelet activation associated with impaired endogenous platelet suppression and endothelial dysfunction is part of the CHF cardiovascular phenotype and leads to the increased risk for thromboembolic complications [13]. Approximately 11–44% of CHF patients will develop thrombotic complications [14]. One of the reasons for this might be a response forms to oxidative stress, which has been proven to be related to the prognosis of cardiovascular diseases [15]. Oxidative stress is defined as the overproduction of reactive oxygen species relative to antioxidant defense and has been shown to play an key role in the pathophysiology of CHF. In addition, it was found that the increase in oxidative stress is related to the functional severity of CHF, with the highest levels being noticed in patients in functional class III and IV [16]. Recent studies have demonstrated that oxidative stress may play a contributing factor in the platelet activation and platelet dysfunction observed in patients with CHF [17–29]. Moreover, previous studies indicated that mean platelet volume [4] and platelet-to-lymphocyte ratio [20–22] are strong and independent prognostic factors in patients with acute heart failure and CHF. Furthermore, Satoshi et al. [2] found that low blood platelet count was linked to all-cause death and cardiogenic readmission to hospital in patients with acute heart failure. Although many predictors of death and hospitalization have been identified, the predictive value of blood platelet count in CHF remains not clear.

**Outcomes and predictors of endpoint events**

The survivals of CHF patients have been found to be influenced by a wide range of demographic, functional, clinical, therapeutic and neurohormonal variables [11, 23]. Consistent with previous studies, we found that a large number of patient factors were associated with adverse outcome of all-cause death and cardiogenic rehospitalization in univariate analyses, and these broadly reflected blood pressure, age, history of CHF, comorbidity and clinical profiles. On multivariate analysis of Cox proportional hazard models narrowed these to lower blood platelet count, advancing age, history of CHF and higher serum hs-TnT. Although advancing age is a risk marker for most adverse events, and history of CHF is unsurprising given that adverse outcome were cardiogenic disease and comorbidity in origin, the other risk markers were potentially anticipated. Indeed, there are no data linking blood platelet count to adverse events in patients with CHF. However, low blood platelet count has been associated with all-cause death and the combine adverse endpoint events in patients with acute heart failure [2].

Previous study showed that thrombocytopenia was associated with 1 year death in patients with CHF with reduced left ventricular ejection fraction (< 40%) [11]. Another recent research revealed that higher blood platelet was a predictors of sepsis death in patients with CHF and reduced left ventricular ejection fraction [24]. A key finding of our study was demonstrated that lower blood platelet count is a dependent risk factor for all-cause death and cardiogenic rehospitalization in patients with CHF. In this study, the outcomes were observed during 3-year follow-up in patients with low platelet count and compared to those with high platelet count. The results of this study is likely agreed with earlier reports in finding that low platelet count increases the risk of all-cause death and readmission to the hospital among acute heart failure patients [2].
Although CHF is a chronic disease, patients often present acute symptoms. The mechanisms responsible for the development of acute attacks and the associated adverse consequences remain unclear. Recent studies demonstrated that acute heart failure was promoted not only by cardiogenic issues but also by systemic pathological changes such as an inflammatory and oxidant state [25]. Blood platelet may reflect those systemic pathological changes and suggest the severity of heart failure acute onset in patients with CHF. Our study included patients with CHF with preserved and reduced left ventricular ejection fraction, and showed that low blood platelet count was associated with adverse prognosis in such patients.

**Study limitations**

Our study provides entirely novel insights regarding the predictors of adverse outcomes in people with CHF. However, it is important to acknowledge the limitations of our study that will need to be addressed by future research. First, our study had a relatively short-term follow-up. Second, we cannot comment on whether lower platelet count underpins the association of our identified risk markers with increased risk of worsened outcomes. Third, the observational nature of our study prevents us from reaching causal inferences about the identified associations of risk markers. Finally, other measured and unmeasured factors might have influential outcomes.

**Conclusions**

In brief, lower blood platelet count may occur with potential pathophysiological changes in CHF. Low blood platelet count was associated with destitute prognosis in patients with CHF. Platelet count is widely measured in clinical conditions and can be easily convenient for use as a risk marker in patients with CHF.

**Declarations**

**Author contributions**

Conception and design of the research: LYB, LZ; Acquisition of data and Analysis and interpretation of the data: JZY, XY; Statistical analysis: JZY, XY; Writing of the manuscript: JZY; Critical revision of the manuscript for intellectual content: LYB, LZ. All authors have read and approved the manuscript.

**Acknowledgements and funding support**

This work was supported by grants from the Guangdong Basic and Applied Basic Research Foundation (2018A030307056) of China; Shantou Science and Technology Plan Project Foundation ([2018]155) of China. The two foundation provide financial support to this study.

**Availability of data and materials**
The data can be obtained from the corresponding author under reasonable request.

**Ethics approval and consent to participate**

The ethics approvals of the retrospective study were obtained from Institutional Ethics Committee at the Beijing Chaoyang Hospital and Second Affiliated Hospital of Shantou University Medical College. Reference number: No. SUMC2020-009. Patients were not required to provide written consent to enter the clinical database, since this was part of the routine clinical operations in the CHF clinic. The data used in this study was anonymized before its use.

**Consent to publish**

Not Applicable.

**Competing interests**

The authors declare that they have no competing interests.

**References**

1. Schildknecht S, van der LB, Weber, Tiefenthaler K, Daiber K, Bachschmid A. M. Endogenous peroxynitrite modulates PGHS-1-dependent thromboxane A2 formation and aggregation in human platelets. Free Radic Biol Med. 2008;45:512–20.

2. Satoshi Y, Masami A, Tomohiro A, Osamu A, Michio S. Incremental Prognostic Value of Platelet Count in Patients With Acute Heart Failure. Circ J. 2019;83:576–83.

3. Karataş MB, Çanga Y, İpek G, Özcan KS, Güngör B, Durmuş G, et al. Mean platelet volume as a predictor of heart failure-related hospitalizations in stable heart failure outpatients with sinus rhythm. Acta Cardiol Sin. 2017;33:292–300.

4. Maciej RC, Zbigniew B, Iwona DN, Tomasz P, Renata, Krzysztof JF. Simple platelet markers: Mean platelet volume and congestive heart failure coexistent with periodontal disease. Pilot studies. Cardiology Journal. 2019;26:253–9.

5. Karataş MB, Çanga Y, İpek G, Özcan KS, Güngör B, Durmuş G, et al. Association of admission serum laboratory parameters with new-onset atrial fibrillation after a primary percutaneous coronary intervention. Coron Artery Dis. 2016;27(2):128–34.

6. Yılmaz F, Köklü E, Kızılirmak YF, Elif SG, Ahmet ŞA, Özlem Y. Evaluation of mean platelet volume and platelet distribution width in patients with asymptomatic intermediate carotid artery plaque. Kardiol Pol. 2017;75(1):35–41.
7. Łysek R, Szafraniec K, Polak M, Piotr J, Agnieszka M, Renata WW, et al. Relationship between past myocardial infarction, periodontal disease and Porphyromonas gingivalis serum antibodies: A case-control study. Cardiol J. 2018;25(3):386–92.

8. Androsz-Kowalska O, Jankowski K, Rymarczyk Z, et al. Correlation between clinical parameters of periodontal disease and mean platelet volume in patients with coronary artery disease: a pilot study. Kardiol Pol. 2013;71(6):600–5.

9. Balduini CL, Noris P. Platelet count and aging. Haematologica. 2014;99:953–5.

10. Westenbrink BD, Voors AA, de Boer RA, Schuringa JJ, Klinkenberg T, Harst PD, et al. Bone marrow dysfunction in chronic heart failure patients. Eur J Heart Fail. 2010;12:676–84.

11. Mojadidi MK, Galeas JN, Goodman-Meza D, Eshtehardi P, Msaouel P, Kelesidis I, et al. Thrombocytopenia as a prognostic indicator in heart failure with reduced ejection fraction. Heart Lung Circ. 2016;25:568–75.

12. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70:776–803.

13. Ulrike F, Daniela F, Julian DW, et al. The Nitric Oxide Donor Pentaerythritol Tetranitrate Reduces Platelet Activation in Congestive Heart Failure. PLoS ONE. 2015;10(4):e0123621. doi:10.1371/journal.pone.0123621.

14. Palka I, Nessler J, Nessler B, Piwowarska W, Tracz W, et al. Altered fibrin clot properties in patients with chronic heart failure and sinus rhythm: a novel prothrombotic mechanism. Heart. 2010;96:1114–8.

15. Paton LN, Mocatta TJ, Richards AM, Winterbourn CC. Increased thrombin-induced polymerization of fibrinogen associated with high protein carbonyl levels in plasma from patients post myocardial infarction. Free Radic Biol Med. 2010;15:223–9.

16. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, OmranAS, Jeejeebhoy KN. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol. 1998;31:1352–6.

17. Mongirdienė A, Laukaityienė J, Skipskis V, Kašauskas A. The Effect of Oxidant Hypochlorous Acid on Platelet Aggregation and Dityrosine Concentration in Chronic Heart Failure Patients and Healthy Controls. Medicina (Kaunas) 2019; 55(5). pii: E198.

18. Mondal NK, Chen Z, Trivedi JR, Sorensen EN, Pham SM, Slaughter MS, et al. Association of Oxidative Stress and Platelet Receptor Glycoprotein GPIba and GPVI Shedding During Nonsurgical Bleeding in Heart Failure Patients With Continuous-Flow Left Ventricular Assist Device Support. ASAIO J. 2018;64(4):462–71.

19. Mondal NK, Chen Z, Trivedi JR, Sorensen EN, Pham SM, Slaughter MS, et al. Oxidative stress induced modulation of platelet integrin α2bβ3 expression and shedding may predict the risk of major bleeding in heart failure patients supported by continuous flow left ventricular assist devices. Thromb Res. 2017;158:140–8.
20. Ye GL, Chen Q, Chen X, Liu YY, Yin TT, Meng QH, et al. The prognostic role of platelet-to-lymphocyte ratio in patients with acute heart failure: A cohort study. Sci Rep. 2019;9(1):10639.

21. Turcato G, Sanchis-Gomar F, Cervellin G, Zorzi E, Sivero V, Salvagno GL, et al. Evaluation of Neutrophil-lymphocyte and Platelet-lymphocyte Ratios as Predictors of 30-day Mortality in Patients Hospitalized for an Episode of Acute Decompensated Heart Failure. J Med Biochem. 2019;38(4):452–60.

22. Durmus E, Kivrak T, Gerin F, Sunbul M, Sari I, Erdogan O. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio are Predictors of Heart Failure. Arq Bras Cardiol. 2015;105(6):606–13.

23. Emdin M, Aimo A, Vergaro G, Bayes-Genis A, Lupón J, Latini R, et al. sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. J Am Coll Cardiol. 2018;72(19):2309–20.

24. Walker AMN, Drozd M, Hall M, Patel PA, Paton M, Lowry J, et al. Prevalence and Predictors of Sepsis Death in Patients With Chronic Heart Failure and Reduced Left Ventricular Ejection Fraction. J Am Heart Assoc 2018; 16;7(20): e009684.

25. Arrigo M, Parissis JT, Akiyama E, Mebazaa A. Understanding acute heart failure: Pathophysiology and diagnosis. Eur Heart J Suppl. 2016;18;G11–8.

Tables

Due to technical limitations, table 1, table 2 and table 3 are only available as a download in the Supplemental Files section.